If patients are loyal to one injector and you are worried about what happens when she leaves, the answer is not to hide her behind your logo. It is to elevate every provider you have, deliberately and publicly, so the practice becomes the thing patients trust and any single calendar becomes replaceable.
Most owners handle this backwards. They either lean entirely on the star injector until she owns a quarter or more of the revenue, a level we treat as the warning line, or they panic and scrub individual names from the website in the hope that the brand absorbs the loyalty. Neither works. In aesthetics, patients are not buying a logo. They are buying judgment and hands. Take the face away and you lower consult conversion without moving the loyalty anywhere, because the patient simply reattaches to whoever she eventually meets in the room.
The real work is a portfolio: every provider gets a face, and the practice owns the standard.
Your practice has a number. Most owners have never looked at it
Before any content strategy, run the diagnostic. You can pull all four of these from your booking software this week.
1. Revenue concentration by provider. What percentage of trailing twelve month treatment revenue sits with each injector? Our threshold: if one person is carrying a third or more of it, that is not a staffing fact. That is a revenue risk with a resignation letter attached to it.
2. First-time versus returning split, by provider. A provider whose book is almost entirely returning patients has a personal panel. A provider who absorbs a healthy flow of new consults is being fed by the practice. The first one walks out with demand. The second one does not, because the demand was never hers.
3. Cross-exposure rate. Of each provider's active patients, how many have ever been treated or even greeted by a second provider in your practice? This is the number almost nobody tracks, and in our read it is the one that tells you most about what happens to a panel after a departure. A patient who has only ever met one person has only ever had a relationship with one person.
4. Review attribution. Pull your recent reviews and count how many name an individual versus the practice. Named reviews are worth collecting: BrightLocal's 2026 Local Consumer Review Survey found 97% of consumers read reviews for local businesses, 47% will not use a business with fewer than 20 reviews, and 74% only care about reviews from the last three months. That recency window is why the ask belongs at every visit, from every provider. But if ninety percent of your reviews name the same person, your public reputation is one provider's reputation.
Four numbers, one afternoon. Seeing them side by side is usually what changes the conversation.
Why hiding your injectors makes it worse
The instinct to de-emphasize individuals comes from a reasonable fear and produces an unreasonable outcome.
Aesthetic buying is high trust and high consequence. A patient considering injectables is evaluating whether this specific person has the eye and the restraint to work on her face. She reads bios. She looks at before and after work and wants to know whose hands produced it. A faceless practice page gives her nothing to evaluate. Our read is that she goes looking elsewhere, usually at a practice that does show its providers.
So the faceless approach, in our experience, costs you new patient conversion, and it does not even solve the problem it was meant to solve. Loyalty still forms. It just forms privately, in the treatment room, where you cannot shape it or share it.
The better position: be visibly proud of every injector on your team, and be equally visible about what makes them yours. Your protocols. Your aesthetic point of view. Your standards for how a result should look. Your consult process. When the practice has a recognisable philosophy, a new provider inherits credibility the day she starts, because she is arriving inside something patients already trust.
The portfolio play
Treat every provider as a named asset, not just the one with a following.
- A real bio page for each provider. Credentials, training, the treatments they are known for, their view on what good work looks like, and their own gallery of results. Not a headshot and a job title.
- Results tied to the provider who produced them. Filterable work galleries and before and after sliders let a patient browse by treatment and by injector. That is how she decides, so build for it.
- Reviews collected at the provider level, from every provider. Make the request part of the visit workflow rather than a monthly scramble. If one injector is generating the reviews because she is the only one being asked, that is an operations choice, not a talent gap.
- Content from the whole team. Technique led, not personality led. Why we dose this way. How we assess a lip. What we will not do and why. Content built around method survives a departure. Content built entirely around one personality leaves with her.
- Two providers in the frame. Video with two injectors discussing a case, teaching each other, disagreeing politely about technique, does more for transferability than any policy document. It tells the patient that the standard lives in the practice.
Build cross-exposure into the visit
Marketing can only do so much if the clinical experience is single threaded. The operational moves are small.
A second provider greets the patient during the visit, by name, once. Combined treatment plans get split across providers where it is clinically sensible. Your consult booking flow offers "earliest available with any of our injectors" as the default, with a named calendar as the alternative rather than the only option. Follow up communication comes from the practice, with the provider named inside it, not from a personal account.
Done consistently, you convert single provider relationships into practice relationships over a year without a single awkward conversation.
She gave notice. Here is the 90 days
Treat it as a marketing operation with a clock on it, not an HR event.
Week one. Segment her panel by value and recency. Top patients by lifetime spend and anyone treated in the last ninety days go on a call list. The owner or medical director calls them personally. Not a text, not an email. The message is simple and not defensive: we are grateful for the time you have spent with us, here is who we are pairing you with and why she is the right fit for your plan, and the transition visit is on us.
Weeks two to four. Everyone else gets an email and SMS sequence from the practice, warm, specific, naming the new provider and linking to her bio and her results. The complimentary follow up with the new provider is the offer. Not a discount. A discount tells a patient her result was never the point.
Days 30, 60 and 90. Run a reactivation sequence against the remainder of the panel, segmented by treatment and by time since last visit. This is where email automation and SMS reactivation earn their keep, because the window where a patient is deciding between following a person and staying with a practice is short.
One caveat before you send anything: panel outreach, patient list segmentation and SMS messaging sit inside patient privacy and messaging consent rules. Clear the sequences and your consent records with your own counsel before launch.
Through all of it, keep publishing. Silence from the practice during a departure reads as instability.
Launch a new injector instead of asking her to build a following
The standard approach is to drop a new provider onto an empty calendar and tell her to build. That guarantees the exact problem you are trying to solve, because the following she builds will be hers.
Launch her instead. Announcement content two weeks before day one. Bio page and gallery live before her first patient. A segment of the practice panel transferred intentionally, not left to chance. An introductory consult offer, free, low pressure, positioned as a conversation. Reviews requested from visit one. Paid and AI visibility campaigns that route new consult demand to her calendar during ramp.
She fills faster, you de-risk the practice, and the demand belongs where it should.
Noncompetes are not a marketing strategy
Restrictive covenants are worth reviewing with your own employment counsel, and enforceability varies by state and by who is being restricted. What is permitted varies by state, by profession and by the terms of the agreement itself, and several states have moved in recent years to limit noncompetes for health care professionals. Your state legislature and the relevant licensing board set the terms where you practice, so check what applies to you there with your own employment counsel. Do not plan around a federal rule arriving to settle this for you. Whether a given clause holds is decided state by state, and your counsel is the one who can read yours against the law where you operate. But containment is not growth. A clause does not fill a chair, and it does nothing on the day the provider has already gone. The practices that survive turnover are the ones that built transferable demand before they needed it.
We build that system for aesthetic practices only: provider bios and galleries, reputation and Google Business Profile work across the whole team, content and video that carries the method rather than one personality, and the email and SMS sequences that hold a panel together when it matters. If you want to know what your concentration number actually is, a free 15 minute discovery call is the fastest way to find out.
Frequently asked questions
How do I measure how exposed my practice is to one injector leaving?
Pull four numbers from your booking software: each provider's share of trailing twelve month treatment revenue, their first-time versus returning patient split, the percentage of their patients who have ever been seen by a second provider, and how many of your recent reviews name an individual versus the practice. Our threshold: if one provider carries a third or more of revenue and her book is mostly returning patients with no cross-exposure, that is concentrated risk. It takes an afternoon to assemble.
Should I take injector names off my website to protect the practice?
No. Aesthetic patients are evaluating judgment and hands, so a faceless page costs you consult conversion while loyalty still forms privately in the treatment room. The stronger position is to give every provider a real bio page and results gallery, then make the practice the common thread through protocols, standards and a clear aesthetic point of view.
What do I do in the first week after a provider resigns?
Segment her panel by lifetime value and recency, then personally call the top patients and anyone treated in the last ninety days. Tell them who they are being paired with and why that provider fits their plan, and offer the transition visit complimentary. Everyone else moves into a warm email and SMS sequence from the practice over the following weeks.
Should I discount to keep patients after an injector leaves?
Offer a complimentary follow up visit with the new provider rather than a price cut. A discount signals that the result was never the point and trains the panel to wait for the next promotion. The goal is to get the patient in front of the new injector once, because the relationship forms in the room.
How should I market a new injector so she is not starting from zero?
Treat it as a launch, not a hiring note. Run announcement content two weeks before day one, have her bio page and gallery live before her first patient, transfer a segment of the practice panel to her deliberately, offer a free introductory consult rather than a discount, and request reviews from her first visit onward. Route new consult demand from paid and AI visibility campaigns to her calendar during ramp.
